Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Several of my colleagues have joined the newsletter today to bring you the latest biopharma updates. It’s a busy news day, especially for a summer Wednesday, so let’s get straight into it.
The need-to-know this morning
- Sage Therapeutics and Biogen said an experimental pill failed to quell involuntary muscle shaking in patients with a neurological condition called essential tremor.
- Geron’s chief commercial officer is leaving the company in August, just two months after the approval of its first medicine, a treatment for a type of blood cancer.
Questions still swirl on Pfizer’s hemophilia A therapy
Pfizer this morning reported that its gene therapy for hemophilia A reduced patients’ bleeds in a late-stage trial. While the results may be enough for the the therapy to win approval, they aren’t likely to quell doubts that the treatment would be a meaningful option for patients.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect